To the Editor: In the article by Manabe and colleagues (1) on Clostridium difficile colitis, only a length of stay of 5 days or longer seems to be of value in managing patients ( Table 1) . The "ideal" high true-positive rate and low negative likelihood ratio make this an excellent screening test for ruling out C. difficile colitis. I disagree that previous use of cephalosporin is an important predictor, because the positive likelihood ratio is too low and the negative likelihood ratio is too high. I recommend that the authors evaluate combinations of historical findings to define a positive index test result (2, 3).
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
• 
Natural History of Polycythemia Vera
To the Editor: The highly informative article from the Gruppo Italiano Studio Policitemia (1) has increased our knowledge of the course of polycythemia vera. Although we endorse most of the author's conclusions, we believe the study has several limitations inherent in its retrospective design.
Although the diagnostic criteria established by the group are useful in the research setting, they tend to be restrictive and may exclude as many as one third of patients who have polycythemia vera but incomplete presentations (2) . In interpreting the Italian group's findings, it seems plausible that some or most of the patients who previously had thromboses were actually presenting at that time with an incomplete form of polycythemia vera. Given the insidious course of the disease, such patients may differ in terms of neoplastic complications from patients who meet the above criteria at the first manifestation of the disease. Thus, they should be analyzed separately. Moreover, the approach to treating these milder cases may have been less aggressive in terms of myelosuppressive agents. Therefore, the outcome in patients with mild disease may have differed considerably with respect to neoplastic complications.
The authors conclude that survival duration in patients with polycythemia vera is longer than previously believed, a result similar to those from several other retrospective studies. Retrospective assessment of survival poses several difficulties. For example, sudden death (such as that from massive myocardial infarction) occurring before diagnosis is established would exclude a patient from the cohort. Therefore, such studies tend to overestimate survival. Another variable affecting survival is that patients who receive a diagnosis earlier in the course of their disease tend to have a longer arithmetic survival. For example, in another study (2) in which 16% of patients with polycythemia vera were identified incidentally while asymptomatic, the overall median survival was 17.4 years.
Our final criticism relates to the conclusion that myelosuppressive agents have an overall unfavorable effect. In their Discussion section, the authors contend that patients receiving myelosuppression therapy may have more severe disease, as supported by the higher frequency of thrombosis. Such potential selection bias precludes a separate assessment of the adverse effects of myelosuppressive agents. Long term follow up in polycythemia vera. Harefuah. 1995;128:673-6.
In response: Shpilberg and Shahar correctly emphasize that the main limitation of our study is inherent in its retrospective design. Thus, any finding should be interpreted cautiously, and any conclusion considered as a working hypothesis should be verified prospectively.
Several hypotheses and open questions exist about the diagnosis of polycythemia vera, given the sparse or outdated data available (1) . Prospective studies of polycythemia vera whose results have been published are limited by small sample size and by discrepancies in inclusion criteria. Apart from the studies of the Polycythemia Vera Study Group (2) and the trial organized by the European Organization for Research on Treatment of Cancer (3) , no other relatively large randomized, controlled trials can be found in the literature. Our retrospective study, although by far the largest in the literature, could not compensate for this lack of knowledge.
As clearly stated in our paper, our primary goal was to provide information for designing clinical trials. Thus, the incidence of thrombotic events in polycythemic patients estimated in the retrospective analysis was used to calculate the sample size for a double-blind, placebo-controlled clinical trial testing low-dose aspirin in patients with polycythemia vera. Our other main objective was to explore the feasibility of organizing an active Italian collaborative group for the study of polycythemia vera. Following this experience, a European Collaboration on Low-dose Aspirin in Polycythemia Vera was established and funded by the European Union BIOMED 2 program. This study is a randomized trial designed to assess the risk-benefit profile of low-dose aspirin in patients with polycythemia vera. Several European countries are involved in the study, which will enroll approximately 3000 patients to be followed for 3 to 4 years. Patient recruitment began in June 1996 and is expected to be completed by December 1998. Patients not randomly assigned to treatment will also be followed. We hope that this prospective study will be helpful in assessing the current natural history of the disease. 
Roberto Marchioli, MD

Diagnosis of Clostridium difficile Colitis
To the Editor: In the article by Manabe and colleagues (1) on Clostridium difficile colitis, only a length of stay of 5 days or longer seems to be of value in managing patients ( Table 1) . The "ideal" high true-positive rate and low negative likelihood ratio make this an excellent screening test for ruling out C. difficile colitis. I disagree that previous use of cephalosporin is an important predictor, because the positive likelihood ratio is too low and the negative likelihood ratio is too high. I recommend that the authors evaluate combinations of historical findings to define a positive index test result (2, 3) .
Rarely does a provider rely on one clinical finding to rule in or rule out a diagnosis. A positive index test result could be defined as a combination of use of antibiotics, antibiotic use for at least 5 days, and semiformed or watery stool. If all three findings were positive, the false-positive rate would be very low and the positive likelihood ratio would be very high. No confirmatory laboratory test, including a C. difficile assay, would be necessary to make a definitive diagnosis. Similarly, the authors could define a positive index test result as a combination of fecal leukocytes, lactoferrin, and positive Gram stain. The use of combinations of clinical characteristics rather than individual tests is valuable in deciding whether to use expensive laboratory tests and is more characteristic of the problem-solving behavior of clinicians.
David A. Nardone, MD Veterans Health Administration Portland, OR 97207
To the Editor: Manabe and colleagues (1) have provided valuable guidelines for diagnosing C. difficile colitis in hospitalized patients. The study group was defined as patients who had C. difficile toxin as shown by enzyme-linked immunoassay or cytotoxin tissue culture assay. Although this definition of C. difficile colitis is adequate for clinical purposes, we should remember that the presence of C. difficile toxin is not always associated with C. difficile colitis. On the basis of a positive cytotoxin tissue culture assay, C. difficile was present in 34 of 268 patients (12.7%) in Manabe and colleagues' study. This prevalence is similar to that of C. difficile positivity seen in 5% to 15% of adults who were treated with antimicrobial agents but did not have related diarrhea (2). Thus, it would be interesting to know the prevalence of C. difficile positivity in the patients in Manabe and coworkers' study who received antibiotics but did not have diarrhea. To the Editor: We thank Manabe and colleagues (1) for their careful examination of the diagnostic aspects of C. difficile diarrhea. Although the case definition required a positive toxin assay result, the sensitivity of a single cytotoxin assay was only 79%. Using different case criteria, other investigators have found the sensitivity of cytotoxin assay to range from 67% to 74% (2).
Manabe and coworkers report that diagnostic sensitivity may be increased by obtaining two to three serial stool specimens for cytotoxin assay. However, Aronsson and colleagues (3) reported that additional specimens increase the rate of detection by only 10%. We suggest the combination of cytotoxin assay and toxigenic culture of the initial specimen as a useful alternative solution to this problem (2) that prevents the need for submitting multiple specimens. If the result of the direct cytotoxin assay is negative and C. difficile is identified on selective medium, the isolate should be tested for elaboration of cytotoxin in vitro. Confirmation of toxigenicity is important because nontoxigenic C. difficile strains are not pathogenic. The addition of culture improves the sensitivity of laboratory diagnosis to as high as 96% (2) and permits strain typing of individual isolates. The latter facilitates recognition of outbreaks of nosocomial infection (4).
We have found this combined diagnostic approach to be convenient, efficient, cost-effective, and reasonably rapid (cytotoxin assays may be completed in 24 hours; toxigenic cultures, in 4 to 5 days). At the University of Colorado, 41 of 120 culture-confirmed cases of C. difficile diarrhea were cytotoxin negative during a 12-month period. Similarly, at Northwestern University's Memorial Hospital, 61 of 160 cases detected during a 6-month period were cytotoxin negative. Because we and others (5) have seen patients who have this disorder but no positive result on direct-stool cytotoxin assay progress to pancolitis or even death, clinicians must recognize the limited sensitivity of cytotoxin assays and the potential utility of culture for the diagnosis of C. difficile diarrhea. To the Editor: Some points made in Manabe and colleagues' article on C. difficile colitis (1) deserve to be amplified. The authors evaluated patients in whom the diagnosis of C. difficile colitis was entertained rather than all patients, or even just patients with diarrhea. Would the conclusions remain the same for patients in whom it was not clear whether the diagnosis of C. difficile colitis should be considered?
Perhaps the patients in whom the duration of diarrhea was longer might be a subgroup worth analyzing. The results of Manabe and colleagues' study were summarized as significant odds ratios for the following four variables: leukocyte positive by lactoferrin assay, positive for fecal leukocytes by Gram stain, recent cephalosporin use, and presence of semiformed stool. It is not immediately clear how sensitive and specific the presence of positive findings for these variables is, alone or in combination, for the diagnosis of G difficile colitis.
Finally, the statistical analysis included stepwise multiple regression. I am surprised that leukocytes positive by lactoferrin and by Gram stain were both shown to be statistically significant; it would seem that the two should not be independent variables. Which independent variables might the two tests be measuring?
Stephen In response: We agree with Dr. Nardone that clinicians use patterns of clinical and laboratory variables to solve problems. We have analyzed the manner in which the sequential addition of our identified predictors affected the diagnosis of C. difficile disease ( Table 2 ). Although this information may be useful, the results are not statistically significant. For practical purposes, physicians will suspect C. difficile-associated enteric complications in any patient with otherwise unexplained diarrhea that occurs with exposure to antibiotics. Decisions about use of laboratory testing are optimally dictated by the effect of the test results on management and by the probability of a positive result. Cephalosporins are the major agents implicated in C. difficile-associated diarrhea in recent years (1, 2) . Usage rates indicate that clindamycin is probably the most commonly used agent, but not enough patients in our series were receiving clindamycin to allow us to verify this well-known association.
Fang and colleagues summarize the findings of some of their previously published reports on the sensitivity of tests for C. difficile toxin. The major point of our paper was not that two to three stool specimens are needed for adequate diagnostic sensi- (5) showed that about 30% of hospitalized patients have C. difficile in the absence of diarrhea; most of these strains are toxigenic. We appreciate the remarks of Drs. Minochi and Richards and agree that the C. difficile toxin assay is associated with falsepositive results. The literature they cite for this conclusion is our own, but it is limited to studies of patients receiving a few antibiotics. We have even greater concern about specificity with culture because of high carriage rates of G difficile, as noted above. However, to keep the observations in perspective, it is important to emphasize that almost all enteric bacterial pathogens are associated with relatively high rates of false-positive results on standard tests. This applies to salmonella, shigella, Vibrio cholerae, Campylobacter jejuni, and other organisms. The requirement for the clinician is clinical correlation.
Dr. Holland correctly points out that both lactoferrin assay and Gram stain provide different ways of measuring the presence of fecal leukocytes. We wish to correct the impression that they were additively predictive of C difficile disease; they were not. We separately analyzed lactoferrin and Gram stain for fecal leukocytes only to validate the utility of lactoferrin as an adjunct in diagnosing G difficile disease.
Surgical Treatment of Asymptomatic Carotid Stenosis
To the Editor: The article by Barnett and colleagues on the surgical treatment of asymptomatic carotid artery disease (1) deserves some clarification. First, the authors appear to misinterpret the failure to find statistically significant effects as implying the absence of an effect. The Asymptomatic Carotid Atherosclerosis Study (ACAS) was not designed to have good power to find differences in "disabling strokes" alone, to compare the treatments in women alone, or to evaluate differences in treatment effect between men and women.
Second, we agree with the authors that Doppler flow velocities reflect the cross-sectional area change of a vessel. It is precisely this measure, and not diameter, that is important for determining arterial pressure and flow. Nonetheless, Barnett and colleagues are wrong to imply that a "60% ACAS Doppler" stenosis is a measurement of area. All Doppler laboratories in the ACAS were validated to diameter measurements provided by arteriograms before being added to the study group. Thus, in the ACAS, 60%, 70%, and 80% Doppler stenoses are equivalent to 84%, 91%, and 96% cross-sectional area narrowing, respectively.
Third, the authors make much of the stroke risk determined by arteriographic linear decile measurements. We await their data showing good interobserver and intraobserver reliability in reading contrast angiograms to the nearest decile. Because the linear diameter of a normal carotid artery on digital minimized film is an average of 3 mm, the measurement of 60%, 70%, and 80% diameter stenosis would require exact measurements of 1.2-, 0.9-, and 0.6-mm minimal residual lumens, respectively. Given the vagaries of patient movement artifact, contrast-dye load and edge definition, projection angle, and intraluminal plaque irregularity, we believe that this task is daunting (perhaps impossible), even if a jeweler's loupe is used.
Finally, it is erroneous and misleading to imply that the results of ACAS are inconclusive. Peer reviewers (who critiqued the study before it began and periodically while it was in progress), the Data and Safety Monitoring Committee, and the unblinded Statistical Coordinating Center certified that the contrary was true. The Data Safety and Monitoring Committee stopped the study earlier than planned because the observed advantage of surgery was greater than we assumed when designing the study. In response: We agree completely that data from trial subgroups should be interpreted cautiously. Nevertheless, it is disappointing that the survival curves for the secondary analysis of disabling stroke remained superimposed for 4.5 years (1). The lack of benefit for women could be due to small numbers rather than an absence of benefit. The perioperative complication rate of stroke in women (3.6%) was double that in men (1.7%).
We did not imply that the ACAS was reporting 60% as an area stenosis. Our comment was that "60% is only equivalent to a linear measurement on an arteriogram if the cut-point formula of ACAS is applied" (2) . We stated that "in clinical practice, the description of a 60% stenosis from a Doppler report may be misinterpreted." Practitioners reading a reported "60% stenosis" are less familiar with the nuances of area and linear measurements than are aficionados. We cautioned the readers of the potential of misrepresenting a ultrasound report that indicates stenosis of 60% by presuming that the report is equivalent to arteriography.
Arteriographic linear measurements remain the standard against which endarterectomy has been evaluated in symptomatic patients. Good interobserver and intraobserver agreements indicate that with care and patience, arteriographic measurements are reproducible (3, 4) . The stakes are high, and additional minutes needed for readings are well spent.
The term "inconclusive" denotes that the ACAS results do not translate readily into clinical usefulness. Symptomatic and asymptomatic patients with severe stenosis face major differences in risk. The stroke rate in the medical therapy group of the North American Symptomatic Carotid Endarterectomy Trial (NASCET) was 13.5% per year; in the ACAS, the rate was 2.2%. If the number of patients needed to treat is used as the measure of greatest clinical importance, 67 asymptomatic patients and 6 symptomatic patients require carotid endarterectomy to prevent one stroke in 2 years. Only skilled surgeons can achieve this result. With the morbidity and mortality rate of 4.5% reported in the other randomized trials on asymptomatic patients, the numbers needed to treat to spare stroke at even the highest degrees of stenosis are prohibitive.
It is disappointing that the ACAS could not identify deciles of stenosis that carry the greatest risk. An annual increase in stroke risk as small as 1% would reduce the number needed to treat from 67 to 28 and perhaps tip the scales in favor of surgery. It is a reasonable hypothesis that in asymptomatic patients with the highest risk (>80% stenosis), favorable benefit will be found. No randomized trial has yet confirmed this hypothesis, but such a finding may emerge from the European Asymptomatic Carotid Surgery Trial (5).
Henry JM. Barnett 
Abuse History and Gastrointestinal Illness
To the Editor: I congratulate Dr. Drossman for his timely review of the management of refractory functional gastrointestinal disorders (1) . He suggests that the predominant symptom should determine the best medication (for example, loperamide for diarrhea and anticholinergic agents for pain). He recommends psychoactive medications when pain is unrelated to changes in gut function, thus downplaying the role of antidepressant agents in functional gastrointestinal disorders in the presence of gut dysfunction. Greenbaum and colleagues (2) have shown a beneficial effect of desipramine on diarrhea and on the abdominal pain in diarrhea-predominant irritable bowel syndrome. Similarly, Cannon and associates (3) have shown that imipramine relieves symptoms in patients who have chest pain despite normal coronary angiograms and regardless of abnormal results of esophageal motility and provocative testing. The mechanism of action of these drugs remains to be established. In response: I appreciate Dr. Minocha's comments, but they require some clarification. In my article, I state that "if pain is the primary problem, it helps to determine whether the pain occurs in relation to changes in gut function, which would indicate the need for a medication directed at the gut (such as an antimotility drug). If the pain is continuous, severe, and unre-lated to changes in gut function, psychoactive medications for central analgesia [antidepressant agents] are indicated." I agree that antidepressant agents can be used in the presence of gut dysfunction; conversely, motility-acting agents are not suited for severe, continuous pain with or without gut dysfunction. In addition to the study by Greenbaum and colleagues (1) (which showed reduction of diarrheal symptoms and the number of slow contractions in the rectosigmoid in patients with diarrhea-predominant irritable bowel syndrome), two recent studies have shown positive effects of antidepressant agents on smallbowel motility (2, 3) . Imipramine, a tricyclic antidepressant agent with substantial anticholinergic effects, was shown to slow jejunal phase III propagation velocity and to prolong orocecal transit time in normal persons and in patients with diarrhea-predominant irritable bowel syndrome (2) . In another study by the same research group (3), administration of paroxetine-a selective serotonin reuptake inhibitor-reduced orocecal transit time in controls and patients with diarrhea-predominant irritable bowel syndrome. No data were available on possible effects on symptoms.
To expand on my previous recommendations, I emphasize three points: First, antidepressant agents may improve symptoms of the irritable bowel syndrome by affecting motility, independent of mood-altering or analgesic effects, but confirmatory studies correlating symptoms with changes in motility and adjusting for depressive mood are needed. A practical approach would be to choose a tricyclic agent with anticholinergic properties for diarrhea-predominant irritable bowel syndrome and a selective serotonin reuptake inhibitor for constipation-predominant irritable bowel syndrome.
Second, motility-altering agents are better suited for treating such symptoms as postprandial pain and diarrhea on an asneeded basis. Conversely, because antidepressant agents require several weeks to become effective and have a long duration of action, they are best prescribed when symptoms are frequent or continuous.
Finally, the role for motility-altering agents in other functional gastrointestinal disorders (for example, functional dyspepsia, esophageal motility disorders, and anorectal disorders) is not well established, requires further study, and must be determined on an individual basis. Because of their central analgesic effects, however, antidepressant agents may help when symptoms are severe and refractory. 
Recognition of IgD and Periodic Fever
To the Editor: The hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) is characterized by recurrent febrile attacks with abdominal symptoms, joint involvement, skin lesions, and lymphadenopathy. The syndrome has been diagnosed in 66 patients, most from Europe (1). The clinical picture and the elevated serum IgD levels (MOO U/mL) complete the diagnosis. Although no treatment is available, a correct diagnosis removes uncertainty and allows the patient to be informed on the benign prognosis of the syndrome.
To our knowledge, HIDS has been diagnosed in only two patients in the United States (2) . Although population variation may explain the lack of cases, we believe that under-reporting of cases plays a substantial role. Possible reasons for such underreporting include lack of awareness and limited availability of
the United States routinely measure IgD levels. In one study (3), laboratories were asked about measurement of IgD levels. All laboratories used one radial immunodiffusion method to assess IgD and measured only a few (<20) samples weekly (3) . Although this method has a limited sensitivity, the range of serum IgD levels in HIDS is such that the diagnosis should be made. However, most samples in the United States are shipped, and IgD is susceptible to spontaneous fragmentation during storage due to proteolytic enzymes that are present in serum and may influence the results (4) 
Meta-Analysis and Bouillabaisse
To the Editor: In his thoughtful editorial on the recent controversy over calcium channel blockers (1), Dr. Messerli correctly points out that the research methods used in two recent studies on this topic (2, 3) are prone to various biases. Although we agree with the general comments made in the editorial, we make three points about the case-control study by Psaty and colleagues (2).
Dr. Messerli states that this study may have been subject to selection bias and that hypertensive patients with coronary artery disease may have been more likely to be treated with calcium antagonists than with diuretics. Psaty and colleagues, however, present results that address this concern: Among persons with cardiovascular disease, 52.5% were receiving diuretics and only 37.4% were receiving calcium channel blockers. Furthermore, all persons with known cardiovascular disease were excluded from the study's principal analysis.
A second form of bias that can arise in case-control studies is recall bias, in which differential recollection of previous exposures can lead to spurious associations between disease and exposure variables. Although recall bias may have affected the recording of potential confounding variables, the exposure variable of medication use was determined from computerized pharmacy data, not from patient recall.
Finally, Psaty and colleagues did their study on a well-defined patient sample-enrollees in the Group Health Cooperative of To the Editor: I read with interest the recent editorial by Dr. Messerli (1). As both a health services researcher-clinical epidemiologist and a practicing general internist, I have found the controversy about calcium channel blockers to be enlightening and frustrating. I strongly agree with Dr. Messerli that controlled studies documenting the safety and efficacy of calcium channel blockers are desperately needed. (It is interesting that such trials have not been done, and yet billions of dollars are spent each year prescribing and marketing these drugs.)
I do, however, disagree with two of his other statements. Messerli correctly states that case-control studies are subject to possible selection bias. This means that if physicians preferentially indicate that patients are at risk for death (presumably because of ischemic heart disease) with calcium channel blockers rather than with other antihypertensive agents, the increased rate of myocardial infarction may be caused by the indication, not the drug. He fails to mention, however, that Psaty and colleagues (2) have shown a clear dose-related decrease in the rate of myocardial infarctions among hypertensive patients receiving j3-blockers (despite a dose-related increase in the rate of myocardial infarction in hypertensive patients receiving calcium channel blockers). j3-blockers are subject to the same selection bias as are calcium channel blockers; however, patients at Group Health Cooperative of Puget Sound who take j3-blockers fare much better than do those who take calcium channel blockers.
Second, Messerli shows results for four placebo-controlled trials indicating that patients who receive long-acting calcium channel blockers survive longer than do patients who receive placebo. This finding is misleading in two ways. First, only one of the trials examined patients with hypertension. Psaty and colleagues did not contend that calcium channel blockers have no potential uses. They clearly state that these agents are associated with increased risk for myocardial infarction in patients with hypertension. Second, the comparison group in each of these studies received a placebo, but none of the Group Health patients in Psaty and colleagues' study did. Patients receiving calcium channel blockers had an increased risk for myocardial infarction compared with patients receiving other drugs. The take-home message from Psaty and colleagues' study was that the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure guidelines (3) should be followed: Hypertension should be initially treated with diuretics or /3-blockers, or both, and calcium channel blockers should be second-or thirdline agents. In response: As Drs. Ghali and Hershman point out, Psaty and colleagues attempted to avoid an indication bias. No matter how carefully a retrospective case control-study is done, however, an indication bias can never be ruled out: In retrospect it is impossible to second guess the reason a specific cardiovascular drug was prescribed for a given patient. In another report from the same patient cohort (1), the authors freely admit that "as expected those with cardiovascular disease were more likely to be taking calcium channel blockers and beta blockers " Because all patients had hypertension (which, by definition, is a cardiovascular disease), it was impossible to exclude persons with known cardiovascular disease.
William M. Tierney, MD
It is by no means unexpected that patients receiving /3-blockers had better outcomes than did those receiving calcium antagonists. Given that most of these short-acting calcium antagonists were not approved for treating hypertension and that they were prescribed at an inappropriate dosing schedule (that is, once a day or twice a day as Dr. Psaty recently conceded [2] ), the outcome is not surprising. Nifedipine capsules given once or twice a day will, at best, decrease arterial pressure for a few hours only and, at worst, lead to hypotension, sympathetic stimulation, reflexive tachycardia, and possibly myocardial ischemia (3). Such a regimen deviates from accepted standards of medical practice, and it should be no surprise when the outcome also deviates from these standards.
Finally, I am not certain about the take-home message of Psaty and colleagues' study to strictly follow the Joint National Committee guidelines. Recent case-control studies (4, 5) have shown an increased risk for sudden death with j3-blockers and diuretics compared with other therapies for hypertension. Interestingly, news media coverage of these reports was minimal compared with that elicited by the calcium antagonists. These data notwithstanding, diuretics are the only drug class for which a reduction in mortality has been unequivocally shown in patients with hypertension. Such data are lacking for all others (such as j3-blockers, a-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers). Why single out calcium antagonists? Perhaps we should be more concerned about the ink that is currently wasted on misleading case-control studies, meta-analyses, and other "bouillabaisse" and about the underlying reasons for the excessive media coverage than about the safety of the long-acting calcium antagonists.
Franz H Messerli, MD
Ochsner Clinic and Alton Ochsner Medical Foundation New Orleans, LA 70121 mean ± SD (range). TGF-/31 = transforming growth factor-/31.
Rating Long-Term Care Facilities on Pressure Ulcers
To the Editor: Berlowitz and colleagues (1) used a large Veterans Administration database to identify clinical and functional status variables that predict pressure ulcer development. Although they refer to poor nutrition as a known risk factor, their multivariable analysis identifies no variable that is closely related to nutritional status. At least three possible explanations exist.
One explanation is simply that the database did not contain information on nutrient intake or "nutritional status." The second is that some nutritional variables were included, but no association was found. The associations among nutrient intake, nutritional status, and the presence or development of pressure ulcers are in fact surprisingly loose (2) . Malnutrition is generally automatically acknowledged as a risk factor, although many studies (perhaps this one) found no association between nutrition and pressure ulcers.
The third possibility is complex. The term "malnourished" can refer to an otherwise healthy, starving child, a case in which providing food would clearly help. The term can also describe a cachectic patient with metastatic lung cancer: All measures of nutritional status are abnormal, but dietary intervention to aid survival is useless. Some nursing home residents may more closely resemble the latter than the former. Nutrient intake and nutritional variables might both be affected (although differently) by chronic, wasting illness or by extreme, fragile debility, but aggressive provision of nutrients would be fruitless.
If analysis of this large database shows no relation between nutrition and development of pressure ulcers, I believe the authors should emphasize this fact. Currently, many persons are attached to feeding tubes or receive dietary supplements on the basis of a belief that such a relation exists.
In response: We agree with Dr. Finucane that the association among nutrient intake, measures of nutritional status, and the development of pressure ulcers is complex. Unfortunately, our database did not contain information on these variables. Such information would have been useful, both to better define this clinical condition and to understand differences in patient mix that may affect a facility's rate of pressure ulcer development. Further studies are needed in this area. 
Dan R Berlowitz, MD, MPH
Elevated Levels of Circulating Transforming Growth Factor-/31 in Patients with the Sepsis Syndrome
To the Editor: The sepsis syndrome is associated with the presence of circulating proinflammatory cytokines. Recent investigations have indicated the presence of naturally occurring antiinflammatory mediators (such as interleukin-lra, soluble tumor necrosis factor receptor [sTNF R], and interleukin-10). Among the anti-inflammatory cytokines, transforming growth factor-/31 (TGF-/31) has been shown to repress the production of inflammatory cytokines by activated macrophages (1) and to induce the release of sTNF R and interleukin-lra (2). Circulating TGF-/31 levels are present in healthy persons, and the role of TGF-/31 in homeostasis has been clearly established in knock-out mice, which die within 3 weeks of developing multifocal inflammatory disease (3).
We investigated whether the levels of circulating TGF-/31 were increased in patients with the sepsis syndrome. We measured the levels of plasma TGF-j31 in 26 patients at the time of diagnosis. As shown in Table 1 , mean plasma levels of TGF-/31 were significantly higher in septic patients than in healthy donors. In 8 patients, the circulating TGF-/31 level was greater than 26.6 ng/mL, which was the highest level observed in the healthy donors. When levels in platelet-poor plasma were measured, the difference between the groups was borderline. Levels of TGF-/31 were not correlated with outcome or other cytokine levels. These results indicate that high levels of circulating TGF-/31 can be associated with the sepsis syndrome. The contribution of platelets as a source of this cytokine in plasma may be increased during sepsis. The immunosuppression seen in experimental sepsis and in patients with the septis syndrome might reflect the presence of increased levels of TGF/31 (4).
In conclusion, it appears that what Louis Pasteur called "Natura medicatrix" when he studied puerperal sepsis (5) occurs in many patients with the sepsis syndrome. In other words, the systemic inflammatory response syndrome is associated not only with the exacerbation of the production of proinflammatory cytokines but also with the increased release of many anti-inflammatory actors, including specific interleukin-1 and tumor necrosis factor inhibitors and such cytokines as interleukin-10 and TGF-/31. 
Non-Insulin-Dependent Diabetes Mellitus Developing during Interferon-a Therapy for Chronic Hepatitis C
To the Editor: Development of non-insulin-dependent (autoimmune) diabetes mellitus has been suggested in patients treated with interferon- a (1-3) . We describe a patient who developed this disease with no evidence of an immune process while receiving interferon-a for hepatitis C.
A 50-year-old man was referred to us because of chronic active hepatitis C. His cousin had insulin-dependent diabetes, but no family member had a history of non-insulin-dependent diabetes. Recombinant interferon-a was started at a dose of 32 million U three times a week. Before therapy, the patient had glucose intolerance. After 1 week of treatment, his fasting plasma blood glucose level was 5.5 mmol/L. After 7 weeks of therapy, the glucose level suddenly increased to 25.6 mmol/L. The patient's hemoglobin A lc value was 9.5%. The thyroid-stimulating hormone value was in the normal range, and tests for thyroid peroxidase antibodies were negative. Interferon-a therapy was discontinued, and diabetes was controlled after 0.55 U of insulin per kg of body weight per day was given for 1 week. The patient's insulin requirement then decreased quickly, and he stopped taking insulin 3 months after discontinuing interferon-a therapy. His glucose levels were well controlled by diet alone. Results of tests for islet-cell antibodies by immunofluorescence and for insulin autoantibodies by immunoprecipitation were negative before interferon-a therapy and 10 days and 1.5 months after interferon-a therapy was discontinued. Results of tests for glutamic acid decarboxylase antibodies by immunoprecipitation were negative 10 days after cessation of interferon-a therapy. The patient's basal and poststimulation C peptide values were not low before, while, or after insulin therapy was received.
Previous reports (1-3) have described patients with islet-cell antibodies and insulin autoantibodies during interferon-a therapy or when diabetes was diagnosed. Pancreatic autoimmunity probably did not occur in our patient because he had no autoimmune markers. Interferon-a could have led to reduced sensitivity of the patient's liver and peripheral tissues to insulin and to exacerbation of preexisting glucose intolerance (4). The high doses of interferon-a our patient received could explain the intensity of the metabolic disorder. We believe that interferon-a can exacerbate glucose intolerance independently of an autoimmune process, especially if given in high doses.
Enoxaparin-Induced Skin Necrosis
To the Editor: Enoxaparin, a low-molecular-weight heparin used to treat and prevent deep venous thrombosis, has been evaluated in several clinical trials (1, 2) . The wide use of the drug makes it imperative that possible side effects, including skin reactions, be studied (3, 4) . We report the rare occurrence of skin necrosis that developed after enoxaparin administration. To our knowledge, previous reports of side effects of enoxaparin have described local skin inflammation and pruritis, but not necrosis. One report (5) noted that a different low-molecularweight heparin caused skin necrosis. We surveyed approximately 8000 subcutaneous injections of enoxaparin (40 mg once a day or 20 mg twice a day) administered in the Meir General Hospital in Kfar-Saba, Israel, in 1993-1994. The only remarkable complications we identified were two cases of skin necrosis.
Patient 1, a 59-year-old woman, had surgery for myoma of the uterus. Because of her history of atrial fibrillation, treatment with enoxaparin, 40 mg in a single daily subcutaneous injection, was initiated. The drug was given alternately in the right and left arms. Six days later, the injection sites on both arms became red, tender, and indurated. A small black area, 25 mm in diameter, appeared on the left arm. Examination of a biopsy specimen of the lesion indicated severe vasculitis in the dermis and in the dermal-epidermal junction. Results of tests of blood clotting and blood count were within normal ranges. Enoxaparin treatment was discontinued, and the necrotic wound was treated with silver sulphadiazine cream. After local debridement, the wound was allowed to close spontaneously.
Patient 2 was a 34-year-old women in her 42nd week of pregnancy. She had a cesarean delivery because of rupture of the uterus and fetal distress. When deep venous thrombosis developed in her right foot after surgery, the patient was treated with 40 mg of subcutaneous enoxaparin injections once a day. The drug was given periumbilically or in either arm. A purple-red, tender area that appeared in the periumbilical region 10 days later became progressively necrotic (Figure 1 ). Examination of a wedge biopsy specimen showed epidermal necrosis and hyalinized vessels with mononuclear perivascular infiltration in the dermis. After local treatment with silver sulphadiazine cream, the necrotic wound was debrided and left to close spontaneously.
Skin necrosis occurring after administration of a low-molecular-weight heparin is rare, and the pathogenesis of this complication is not well understood. Our experience may alert medical personnel to the possibility of such a side effect. 
Use of Pulse Oximetry for Assessing Ulnar Collateral Flow
To the Editor: O'Mara and Sullivan (1) report the anecdotal use of pulse oximetry for evaluating collateral patency before radial artery cannulation, and they propose that the technique be called the Sullivan test. Other reports on this use of finger pulse oximetry and pulse transduction have been published, and there is a potentially important distinction between the two methods.
Fuhrman and colleagues (2) found that finger plethysmography could detect abnormal circulatory patterns but that significant changes in blood flow in the hand did not result in decreased oxyhemoglobin saturation as assessed by pulse oximetry. They concluded that "plethysmography can be used to demonstrate palmar collateral circulation, but pulse oximetry cannot." On the basis of results of their own studies, Glavin and Jones (3) recommended that pulse monitors and pulse oximetry not be used together for this purpose.
Notwithstanding the controversy over the necessity of collateral flow assessment in general (4) and the findings of Glavin and Jones (3), it appears that finger pulse detection may have merit for assessing ulnar collateral flow. However, further study is required before pulse oximetry can be routinely recommended for this application.
In response: Ulnar collateral circulation should be assured before a procedure is done, given the reported incidence of radial artery thrombosis or occlusion and the reported lack of ulnar collateral flow in 5% to 6% of patients (1). The Allen test has been historically recommended for the bedside screening of ulnar flow (2). Case reports of limb ischemia after radial artery cannulation despite a negative Allen test result have been attributed to emboli (3), not inadequate ulnar collateral circulation that was undetected.
The use of pulse oximetry has been recommended for enhancing the interpretation of results of this test and has been modified for critically ill or uncooperative patients. In pulse oximetry and the Allen test, the results are merely positive or negative and cannot be interpreted as more than that. Both tests identify patients whose low flow state or undetected ulnar flow with radial artery occlusion places them at risk. The Allen test, however, requires patient cooperation. These tests may erroneously exclude some patients who have subclinical flow that could be detected by other means.
Clinicians need to know whether subtler flow changes are significant, and they place patients at greater risk by doing radial artery puncture or cannulation. However, Williams and Schenken (4) reviewed 9020 cases in the literature and their own experience with more than 25 000 radical artery punctures. They found that these procedures were all done with no ischemic complications and concluded that the risk for complication is so low that prescreening with an Allen test is unwarranted. This conclusion would not be useful in the patient in the intensive care unit who is likely to be at higher risk for ischemia because of the use of vasoactive drugs and hypotension. Cases of false-negative ulnar flow and false-positive ulnar flow should be identified. Glavin and Jones reported a sensitivity of 1.0 for oximetry compared with Doppler analysis of ulnar flow. Interestingly, they cited seven patients in their group in whom flow was detected by oximetry but not by Doppler. Unfortunately, they had no patients in whom oximetry failed to detect flow. This finding limits their conclusions. My colleagues and I have frequently identified patients in whom ulnar flow was compromised enough to warrant use of another site.
I agree with Dr. Kruse that diagnostic groups in which oximetry is not useful must be reported. We want to avoid the chauvinism of the Allen test, which may erroneously exclude too many cases from radial use, and the liberalism of "no testing," which may cause complications in the critically ill patient even if it does not cause complications in the general hospital population.
Microsporidia in Humans
To the Editor: Microsporidia are ubiquitous, obligate intracellular parasites that can infect all classes of animals. Five genera-Enterocytozoon, Encephalitozoon, Septata, Pleistophora, and Nosema-and a sixth taxon, which contains unclassified microsporidia, infect humans (1, 2). The sources and modes of transmission remain unknown (1, 2). Microsporidia species infect the central nervous system in animals, but brain involvement in humans has not been reported (2) .
A The autopsy was limited to the brain and showed an organism that resembled both Pleistophora and Thelohania species. The exact identification of the infecting organism awaits further analysis (3).
Toxoplasma gondii is the most common opportunistic pathogen causing focal central nervous system lesions in patients with the acquired immunodeficiency syndrome (AIDS). Infection with this organism was unlikely in our patient because of trimethoprimsulfamethoxazole prophylaxis, a negative serologic result for T. gondii (4) , and the many central nervous system lesions.
The standard approach to central nervous system lesions in patients with AIDS is empirical therapy for toxoplasmosis; refractory cases are considered for brain biopsy. A more aggressive approach to central nervous system lesions may be needed in a select subset of patients with AIDS. Earlier diagnosis might lead to administration of appropriate therapy and could prevent potential toxicities from empirical therapy. Albendazole may be used to treat central nervous system microsporidiosis. This drug is also effective for microsporidial diarrhea (5) and in other parasitic infections of the brain.
Recognition of central nervous system microsporidiosis may contribute to better management of HIV-infected patients. 
Enteroadherent efl&4-Positive Escherichia coli
Associated with Chronic AIDS-Related Diarrhea
To the Editor: Chronic diarrhea is a substantial contributor to morbidity in patients with human immunodeficiency virus (HIV) infection. Even after extensive evaluation, a pathogen often cannot be identified (1) . Recent studies of patients with diarrhea associated with the acquired immunodeficiency syndrome have described histopathologic findings of enteroadherent bacteria that produced attaching and effacing (AE) lesions on the intestinal cell (2, 3) . Such lesions are virulent characteristics expressed by the chromosomally encoded eaeA gene cluster of enteropathogenic Escherichia coli (EPEC). None of the bacteria recovered in these studies carried the eaeA gene (2, 3) .
We report the isolation of an unusual EPEC-like strain in an HIV-infected man with a 10-month history of chronic, intermittent diarrhea and a weight loss of 9 kg. When diarrhea began, the patient's CD4 count was less than 100 cells/mm 3 . He had been receiving a combination of zidovudine and didanosine and treatment for presumptive disseminated Mycobacterium avium complex disease and antipneumocystosis prophylaxis. Examination of an ileal biopsy specimen showed intracellular Enterocytozoon bieneusi sporoblasts and spores. Examination of a colonic biopsy specimen showed multiple superficial V-shaped mucosal ulcers containing aggregates of small bacillary organisms. Some of these clearly produced AE lesions, as shown by electron microscopic examination (Figure 1) . A stool sample was guaiac negative, and cultures yielded predominant non-lactose-fermenting, indole-negative E. coli. The latter could not be typed and was nonmotile. Strong evidence supports the pathogenic role of the isolate: 1) Molecular studies showed that the isolate was positive for eae by polymerase chain reaction (PCR) or colony hybridization and was negative for the EPEC-specific locus of the EPEC adherence factor and bundle-forming pilus gene or with the E. co/i-specific enterotoxin probes (4); 2) the fluorescent actin stain assay showed the AE interaction between the nonlactose-fermenting isolate and HCT-8 cells; and 3) the patient's diarrhea resolved promptly after treatment with oral ciprofloxacin (no treatment was given for the microsporidia).
Further prospective studies are needed to elucidate the role of potentially diarrheagenic E. coli organisms in chronic diarrhea and the related wasting syndrome seen in HIV-infected patients. a related issue that also appears to have been sidestepped is a delineation of the exact role the Board (and other internal medicine groups) should have in the downsizing process. As the total number of training slots decreases, exactly how should accreditation be used to ensure that only the best programs remain within each subspecialty? I fear that Dr. Weiner has missed the point. The American Board of Internal Medicine and other certification boards have a single, critical function: to ensure that certified specialists and subspecialists meet certain criteria of excellence in the areas of medical knowledge and skill (within the limitations imposed by a tough examination). They should never be called on to become the instruments of "downsizing" teaching programs. The only role they should play is an indirect one, by indicating the success of specific programs in generating board-certified graduates. To do more would represent a dreadful conflict of interest and would be counterproductive to the mission of the boards.
As Langdon and colleagues state, "the primary interest of the American Board of Internal Medicine is the quality of training of internists; ways to finance graduate medical education are beyond the Board's purview." So it should remain.
It is painfully evident, however, that unless the U.S. Congress has sufficient wisdom to create fire-walled funding, the enlightened program envisioned by the Task Force will never come to fruition. This would jeopardize the entire structure of basic research, clinical investigation, and teaching-the total contemporary medical enterprise-in the foreseeable future. One could expand this dream to suggest that necessary revenue could be derived from insurers and managed care organizations; from a levy on medical licenses and relicensure; or from a surtax on cigarettes, alcohol, handguns, and ammunition. This revenue could ensure the survival and growth of this carefully and painstakingly wrought intellectual treasure.
I have faith that many capable and visionary legislators will appreciate the enormous stakes involved. I believe that after all the tumult and shouting die, they will do the right thing.
Robert M. Moser, MD
Canyon Consulting Corp. Chama, NM 87920 optimal. We foresee that subspecialty clinicians will probably need a broader range of clinical skills and will be called on to act as principal care providers. For this reason, the investigator pathway requires at least 12 to 24 months of clinical training, appropriate for each subspecialty. Nevertheless, the Board would agree that a subspecialist who changes his or her career direction from investigator to clinician is likely to require additional clinical knowledge and experience. If such a career change occurs during training, the Board will require that additional clinical training be obtained before admission to the subspecialty certification examination. If a career change occurs after training, appropriate continuing medical education becomes the professional responsibility of the individual physician.
Lynn O. Langdon 
Internal Medicine and Family Medicine
To the Editor: In his article on the differences between internal and family medicine practitioners (1), Dr. Saultz did not mention a potential way to facilitate collaboration between the two disciplines. The American Board of Internal Medicine and the American Board of Family Medicine co-sponsor an examination that leads to a Certificate of Added Qualification in Geriatric Medicine. Because residency review committees for both disciplines require each discipline to provide geriatric medical education, internal medicine and family medicine faculty can join in housestaff training. Exposure to the multidisciplinary model necessary to manage the increasing number of functionally impaired elderly is very important for trainees in both specialties. This approach can serve as an academic model of collaboration.
Clifford F. Feiner, DO
Mount Sinai Services at Queens Hospital Center Jamaica, NY 11432
To the Editor: Dr. Saultz (1) makes realistic comparisons and contrasts between family medicine and internal medicine in terms of educational experience and practice style and philosophy. Concerns about practical aspects of cross-coverage, redistribution of patient demographic characteristics, and internists caring for children within these practices are relevant and remotely feasible. The prospect of involving pediatricians in this collaboration, however, is less than likely. Pediatrics has never had a close relationship with family medicine, and it diverged on its own primary care path 15 years before the American Academy of General Practice was formed in 1947.
In 1967, the boards for internal medicine and pediatrics recognized the collaborative training of medicine-pediatrics physicians. As managed care evolved from the changing medical environment, the scope of care among primary care specialists narrowed (2) . This evolution contributed to a 20-fold growth in the number of medicine-pediatrics programs from 1980 to 1990. Specialty acceptance is evidenced by the 1400 graduates in private practice, the 1000 residents in training, and national representation through membership in the Primary Care Organizations Consortium.
This unique primary care specialist also cares for families and provides the ideal collaborative partner with family medicine by overcoming the concerns acknowledged by Dr. Saultz. Managed care utilization data and coding demographic characteristics for family medicine/medicine-pediatrics collaborative practices were recently presented (3) . Collaborative practices showed a 19% to 64% reduction in utilization variables compared with communitybased practices; family physicians made 40% of internal referrals to collaborative medicine-pediatrics physicians that would have otherwise been made to subspecialists. In effect, the competitive system of generalist physicians in separate practices results in family physicians feeding the imbalance between subspecialists and generalists.
These results show that collaborative practice partnerships are efficient. Continued discussion between family medicine and internal medicine would benefit from input from medicine-pediatrics. Thirty years of medicine-pediatrics experience offers an effective collaborative perspective in primary care. This is particularly relevant if the gap in pediatric training within the family medicine-internal medicine collaboration is to be reduced. and health maintenance) (3) . Similarly, family medicine emphasizes primary care skills for managing the needs of ambulatory patients. These skills include an epidemiologic approach (such as prevalent diseases and problems), prevention (such as screening methods), patient education (such as self-care), office administration, and team work and resources use (such as family support and community resources).
Psychosocial skills are essential for an adequate general internist-patient relationship (4) . Similarly, family medicine emphasizes the development of psychosocial skills and the improvement of the physician-patient relationship. For example, by using the biopsychosocial model or systems approach, the patient is not a disease but a person, and health is influenced by many nonmedical factors (such as context and lifestyle) and biochemical interactions. In addition, understanding the patient as a person and developing psychosocial skills help to improve an internist's humanistic qualities (5) .
Finally, both disciplines might work together in education and practice with similar goals, enrich each other, and improve the care of their patients. 
